Nonclinical precedent Request an invite
Species
Rabbit and dog (IVT ocular studies); rat and cynomolgus monkey (7-day IV); monkey the only pharmacologically relevant species
“The monkey is the only species identified that could be considered relevant showing 1/10th of the ARC1905 in an in vitro activity assay against human C5.”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗
Why that species
Human C5 aptamer: monkey 1/10th and rat 1/1000th of human activity; rabbit/dog expected very low activity but accepted for ocular tolerability
“The ocular studies were conducted in rabbit and dogs, which, as the Applicant indicated, are species in which ARC1905 is expected to have very low activity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗
Surrogate molecule
No surrogate; clinical aptamer (ARC1905) tested in non-pharmacologically-relevant ocular species plus IV monkey
“There are no animal species in which the human anti-C5 aptamer can be tested in ocular toxicity studies for effects stemming from C5 binding.”
✓ VerifiedFDA pharmacology/toxicology review, p. 36Source ↗
Species: general tox
New Zealand White rabbit and Beagle dog (repeat-dose intravitreal)
“Repeat-dose IVT toxicity studies were conducted in New Zealand White rabbits (0, 0.15, 0.5, and 1.5 mg/eye) and Beagle dogs (0, 0.3, 1, and 3.0 mg/eye).”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Species: DART
Rat and rabbit (EFD only); fertility and pre/postnatal studies waived
“In the embryofetal development (EFD) toxicity studies in rats and rabbits, there was no avacincaptad pegol-related adverse effects on any measured maternal or fetal parameter at doses up to 1.2 mg/kg/day (NOAEL).”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Species: carcinogenicity
Not conducted (waiver)
“No studies were conducted. The Applicant submitted a justification to support a waiver request not to conduct the carcinogenicity studies”
✓ VerifiedFDA pharmacology/toxicology review, p. 69Source ↗
Surrogate used in
No surrogate used; no species allows testing of C5-related ocular effects
“There are no animal species in which the human anti-C5 aptamer can be tested in ocular toxicity studies for effects stemming from C5 binding.”
✓ VerifiedFDA pharmacology/toxicology review, p. 36Source ↗

Same question, other oligonucleotides

Amondys 45

casimersen · DMD exon 45 (PMO)
Adult male mouse and cynomolgus monkey; juvenile male rat

Amvuttra

vutrisiran · TTR (siRNA)
Rat and cynomolgus monkey (monkey only pharmacologically active; rat for off-target/class tox); rabbit EFD

Dawnzera

donidalorsen · Prekallikrein / KLKB1 (ASO)
Mouse (CD-1) and cynomolgus monkey

Defitelio

defibrotide · Fragmented DNA oligonucleotides
Rat and dog

Exondys 51

eteplirsen · DMD exon 51 (PMO)
Cynomolgus monkey and juvenile rat (eteplirsen); mdx/C57BL mouse incl. mouse surrogate

Givlaari

givosiran · ALAS1 (siRNA)
Rat and cynomolgus monkey (both pharmacologically active); rabbit inactive (EFD only)

Hibsago

bepirovirsen · HBV RNA (ASO)
Mouse and rabbit in labeled studies (carcinogenicity, reproduction); general-toxicity species not stated

Kynamro

mipomersen · APOB (ASO)
Mouse, rat and cynomolgus monkey (clinical ASO plus rodent surrogates)

Leqvio

inclisiran · PCSK9 (siRNA)
Rat and cynomolgus monkey (both pharmacologically active); rabbit for EFD

Macugen

pegaptanib · VEGF-165 (aptamer)
Rabbit and dog (pivotal IVT); rat IV for systemic; supportive monkey, mouse

Onpattro

patisiran · TTR (siRNA)
Rat and cynomolgus monkey (monkey pharmacologically active; rat off-target/LNP)

Oxlumo

lumasiran · HAO1 (siRNA)
Rat and cynomolgus monkey (both pharmacologically relevant); rabbit for EFD

Qalsody

tofersen · SOD1 (ASO)
Cynomolgus monkey (IT, relevant species), CD-1 mouse (SC) and rat single-dose IT

Qfitlia

fitusiran · Antithrombin / SERPINC1 (siRNA)
Healthy rat and cynomolgus monkey (GLP); hemophilia A mouse, hemophilia A dog and induced-HA monkey models

Redemplo

plozasiran · APOC3 (siRNA)
Rat (off-target toxicity) and cynomolgus monkey (pharmacologically relevant)

Rivfloza

nedosiran · LDHA (siRNA)
Cynomolgus monkey (relevant) plus mouse (nedosiran inactive; off-target assessment)

Rytelo

imetelstat · Telomerase (oligo)
Mouse and cynomolgus monkey (general tox); mouse and rabbit (EFD)

Spinraza

nusinersen · SMN2 (ASO)
Juvenile cynomolgus monkey (IT) and CD-1 mouse (SC, systemic effects)

Tegsedi

inotersen · TTR (ASO)
Mouse, rat and cynomolgus monkey; monkey the only pharmacologically relevant species

Tryngolza

olezarsen · APOC3 (ASO)
Mouse (with surrogate) and cynomolgus monkey

Viltepso

viltolarsen · DMD exon 53 (PMO)
Male CD-1 mouse and male cynomolgus monkey (plus juvenile male mouse)

Vitravene

fomivirsen · CMV IE2 mRNA (ASO)
Rabbit and monkey

Vyondys 53

golodirsen · DMD exon 53 (PMO)
Mouse, cynomolgus monkey (adult males) and juvenile rat

Wainua

eplontersen · TTR (ASO)
Mouse and cynomolgus monkey (monkey the pharmacologically relevant species)

Waylivra

volanesorsen · APOC3 (ASO)
Mouse, rat and cynomolgus monkey (rabbit for embryo-fetal); monkey most relevant

Zanvastro

zilganersen · GFAP (ASO)
Mouse (SC and ICV, juvenile) and juvenile monkey (intrathecal); mouse surrogate ASO arm

Summary across all 27 oligonucleotides →